About Symbio Proinnovera
In November 2023 the merger of US-headquartered Symbio LLC with Münster-based Proinnovera created Symbio Proinnovera, one of the world’s largest specialized dermatology-focused clinical research organizations offering cost saving, time-efficient outsourced services for dermatological therapy formulation and clinical trial testing.
The merged group, Symbio Proinnovera, provides consulting, testing and clinical research through every development stage, from conception to global regulatory approval and commercialization. After decades of running dermatology trials, both companies have built valuable data bases that focus and shorten trials in this therapeutic area. As proven market leaders among specialty dermatology CROs with exceptional geographical coverage, their combined strength enables them to excel at addressing customers’ needs and expectations in all areas of research. The two highly accomplished teams with deep expertise in the dermatology space generate efficiencies and accelerate clinical research.
Symbio Proinnovera is supported by ARCHIMED, a leading international investment firm focused exclusively on healthcare industries. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner.
Responsibilities:
Requirements
Last updated on Apr 26, 2024
New York, New York
·30+ days ago
Münster, North Rhine-Westphalia
·30+ days ago
Dortmund, North Rhine-Westphalia
·30+ days ago
Münster, North Rhine-Westphalia
·30+ days ago
Lyon, Auvergne-Rhône-Alpes
·30+ days ago